Nuvectis Pharma, Inc. — Director's Dealing 2023

Jun 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2023-06-16

Reporting Person: Kaplan Matthew L. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-16	Common Stock	A	18000	—	Acquired	53760	Direct

Footnotes

F1: The 18,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the board on such dates.